{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:36:42Z","timestamp":1784907402495,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HD036071"],"award-info":[{"award-number":["HD036071"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007857","name":"Intellectual and Developmental Disabilities Research Center","doi-asserted-by":"publisher","award":["U54HD079125"],"award-info":[{"award-number":["U54HD079125"]}],"id":[{"id":"10.13039\/100007857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s12035-018-1330-3","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:21:38Z","timestamp":1536106898000},"page":"3702-3713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor\/Ataxia Syndrome: a Pilot Study"],"prefix":"10.1007","volume":"56","author":[{"given":"Eleonora","family":"Napoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika Roa","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rogawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi J.","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-7435","authenticated-orcid":false,"given":"Cecilia","family":"Giulivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"1330_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0074-7742(01)46058-2","volume":"46","author":"SH Mellon","year":"2001","unstructured":"Mellon SH, Vaudry H (2001) Biosynthesis of neurosteroids and regulation of their synthesis. Int Rev Neurobiol 46:33\u201378","journal-title":"Int Rev Neurobiol"},{"key":"1330_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0248-4900(91)90045-O","volume":"71","author":"EE Baulieu","year":"1991","unstructured":"Baulieu EE (1991) Neurosteroids: a new function in the brain. Biol Cell 71:3\u201310","journal-title":"Biol Cell"},{"key":"1330_CR3","doi-asserted-by":"publisher","first-page":"14602","DOI":"10.1073\/pnas.0606544103","volume":"103","author":"RC Agis-Balboa","year":"2006","unstructured":"Agis-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Guidotti A (2006) Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci U S A 103:14602\u201314607. \n                    https:\/\/doi.org\/10.1073\/pnas.0606544103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1330_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0079-6123(08)81011-4","volume":"181","author":"G Pelletier","year":"2010","unstructured":"Pelletier G (2010) Steroidogenic enzymes in the brain: morphological aspects. Prog Brain Res 181:193\u2013207. \n                    https:\/\/doi.org\/10.1016\/S0079-6123(08)81011-4","journal-title":"Prog Brain Res"},{"key":"1330_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/B978-0-444-53630-3.00008-7","volume":"186","author":"DS Reddy","year":"2010","unstructured":"Reddy DS (2010) Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 186:113\u2013137. \n                    https:\/\/doi.org\/10.1016\/B978-0-444-53630-3.00008-7","journal-title":"Prog Brain Res"},{"key":"1330_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/nrn1703","volume":"6","author":"D Belelli","year":"2005","unstructured":"Belelli D, Lambert JJ (2005) Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 6:565\u2013575. \n                    https:\/\/doi.org\/10.1038\/nrn1703","journal-title":"Nat Rev Neurosci"},{"key":"1330_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pneurobio.2013.09.003","volume":"113","author":"C Schule","year":"2014","unstructured":"Schule C, Nothdurfter C, Rupprecht R (2014) The role of allopregnanolone in depression and anxiety. Prog Neurobiol 113:79\u201387. \n                    https:\/\/doi.org\/10.1016\/j.pneurobio.2013.09.003","journal-title":"Prog Neurobiol"},{"key":"1330_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pneurobio.2013.09.004","volume":"113","author":"M Schumacher","year":"2014","unstructured":"Schumacher M, Mattern C, Ghoumari A, Oudinet JP, Liere P, Labombarda F, Sitruk-Ware R, De Nicola AF et al (2014) Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog Neurobiol 113:6\u201339. \n                    https:\/\/doi.org\/10.1016\/j.pneurobio.2013.09.004","journal-title":"Prog Neurobiol"},{"key":"1330_CR9","doi-asserted-by":"publisher","first-page":"13807","DOI":"10.1073\/pnas.0606218103","volume":"103","author":"SJ Langmade","year":"2006","unstructured":"Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, Mellon SH, Walkley SU, Covey DF et al (2006) Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc Natl Acad Sci U S A 103:13807\u201313812. \n                    https:\/\/doi.org\/10.1073\/pnas.0606218103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1330_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1210\/en.2012-1772","volume":"154","author":"Y Pang","year":"2013","unstructured":"Pang Y, Dong J, Thomas P (2013) Characterization, neurosteroid binding and brain distribution of human membrane progesterone receptors delta and {epsilon} (mPRdelta and mPR{epsilon}) and mPRdelta involvement in neurosteroid inhibition of apoptosis. Endocrinology 154:283\u2013295. \n                    https:\/\/doi.org\/10.1210\/en.2012-1772","journal-title":"Endocrinology"},{"key":"1330_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.devbrainres.2004.07.009","volume":"153","author":"EA Keller","year":"2004","unstructured":"Keller EA, Zamparini A, Borodinsky LN, Gravielle MC, Fiszman ML (2004) Role of allopregnanolone on cerebellar granule cells neurogenesis. Brain Res Dev Brain Res 153:13\u201317. \n                    https:\/\/doi.org\/10.1016\/j.devbrainres.2004.07.009","journal-title":"Brain Res Dev Brain Res"},{"issue":"Suppl 2","key":"1330_CR12","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1471-2202-9-S2-S11","volume":"9","author":"JM Wang","year":"2008","unstructured":"Wang JM, Brinton RD (2008) Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. BMC Neurosci 9(Suppl 2):S11. \n                    https:\/\/doi.org\/10.1186\/1471-2202-9-S2-S11","journal-title":"BMC Neurosci"},{"key":"1330_CR13","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1523\/JNEUROSCI.4520-04.2005","volume":"25","author":"JM Wang","year":"2005","unstructured":"Wang JM, Johnston PB, Ball BG, Brinton RD (2005) The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 25:4706\u20134718. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.4520-04.2005","journal-title":"J Neurosci"},{"key":"1330_CR14","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jnc.13693","volume":"139","author":"M Karout","year":"2016","unstructured":"Karout M, Miesch M, Geoffroy P, Kraft S, Hofmann HD, Mensah-Nyagan AG, Kirsch M (2016) Novel analogs of allopregnanolone show improved efficiency and specificity in neuroprotection and stimulation of proliferation. J Neurochem 139:782\u2013794. \n                    https:\/\/doi.org\/10.1111\/jnc.13693","journal-title":"J Neurochem"},{"key":"1330_CR15","doi-asserted-by":"publisher","first-page":"6498","DOI":"10.1073\/pnas.1001422107","volume":"107","author":"JM Wang","year":"2010","unstructured":"Wang JM, Singh C, Liu L, Irwin RW, Chen S, Chung EJ, Thompson RF, Brinton RD (2010) Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 107:6498\u20136503. \n                    https:\/\/doi.org\/10.1073\/pnas.1001422107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1330_CR16","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.neurobiolaging.2011.06.008","volume":"33","author":"C Singh","year":"2012","unstructured":"Singh C, Liu L, Wang JM, Irwin RW, Yao J, Chen S, Henry S, Thompson RF et al (2012) Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol Aging 33:1493\u20131506. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.06.008","journal-title":"Neurobiol Aging"},{"key":"1330_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nm1073","volume":"10","author":"LD Griffin","year":"2004","unstructured":"Griffin LD, Gong W, Verot L, Mellon SH (2004) Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 10:704\u2013711. \n                    https:\/\/doi.org\/10.1038\/nm1073","journal-title":"Nat Med"},{"key":"1330_CR18","first-page":"19","volume":"22","author":"J He","year":"2004","unstructured":"He J, Hoffman SW, Stein DG (2004) Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor Neurol Neurosci 22:19\u201331","journal-title":"Restor Neurol Neurosci"},{"key":"1330_CR19","doi-asserted-by":"publisher","first-page":"e24293","DOI":"10.1371\/journal.pone.0024293","volume":"6","author":"S Chen","year":"2011","unstructured":"Chen S, Wang JM, Irwin RW, Yao J, Liu L, Brinton RD (2011) Allopregnanolone promotes regeneration and reduces beta-amyloid burden in a preclinical model of Alzheimer's disease. PLoS One 6:e24293. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0024293","journal-title":"PLoS One"},{"key":"1330_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1089\/neu.2005.22.106","volume":"22","author":"M Djebaili","year":"2005","unstructured":"Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG (2005) The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 22:106\u2013118. \n                    https:\/\/doi.org\/10.1089\/neu.2005.22.106","journal-title":"J Neurotrauma"},{"key":"1330_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.brainres.2009.01.045","volume":"1263","author":"I Sayeed","year":"2009","unstructured":"Sayeed I, Parvez S, Wali B, Siemen D, Stein DG (2009) Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res 1263:165\u2013173. \n                    https:\/\/doi.org\/10.1016\/j.brainres.2009.01.045","journal-title":"Brain Res"},{"key":"1330_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1152\/jn.00730.2012","volume":"109","author":"V Conde","year":"2013","unstructured":"Conde V, Palomar FJ, Lama MJ, Martinez R, Carrillo F, Pintado E, Mir P (2013) Abnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutation. J Neurophysiol 109:1315\u20131322. \n                    https:\/\/doi.org\/10.1152\/jn.00730.2012","journal-title":"J Neurophysiol"},{"key":"1330_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fnmol.2016.00071","volume":"9","author":"C Giulivi","year":"2016","unstructured":"Giulivi C, Napoli E, Tassone F, Halmai J, Hagerman R (2016) Plasma biomarkers for monitoring brain pathophysiology in FMR1 premutation carriers. Front Mol Neurosci 9:71. \n                    https:\/\/doi.org\/10.3389\/fnmol.2016.00071","journal-title":"Front Mol Neurosci"},{"key":"1330_CR24","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1042\/BCJ20160585","volume":"473","author":"C Giulivi","year":"2016","unstructured":"Giulivi C, Napoli E, Tassone F, Halmai J, Hagerman R (2016) Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation. Biochem J 473:3871\u20133888. \n                    https:\/\/doi.org\/10.1042\/BCJ20160585","journal-title":"Biochem J"},{"key":"1330_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.brainres.2008.11.075","volume":"1253","author":"C D'Hulst","year":"2009","unstructured":"D'Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, De Deyn PP, Hassan BA et al (2009) Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor\/ataxia syndrome (FXTAS). Brain Res 1253:176\u2013183. \n                    https:\/\/doi.org\/10.1016\/j.brainres.2008.11.075","journal-title":"Brain Res"},{"key":"1330_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.57.1.127","volume":"57","author":"RJ Hagerman","year":"2001","unstructured":"Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B et al (2001) Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57:127\u2013130","journal-title":"Neurology"},{"key":"1330_CR27","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/mds.21493","volume":"22","author":"E Berry-Kravis","year":"2007","unstructured":"Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, Grigsby J, Bourgeois JA et al (2007) Fragile X-associated tremor\/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 22:2018\u20132030, quiz 2140. \n                    https:\/\/doi.org\/10.1002\/mds.21493","journal-title":"Mov Disord"},{"key":"1330_CR28","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/hmg\/dds118","volume":"21","author":"Z Cao","year":"2012","unstructured":"Cao Z, Hulsizer S, Tassone F, Tang HT, Hagerman RJ, Rogawski MA, Hagerman PJ, Pessah IN (2012) Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum Mol Genet 21:2923\u20132935. \n                    https:\/\/doi.org\/10.1093\/hmg\/dds118","journal-title":"Hum Mol Genet"},{"key":"1330_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/cge.12646","volume":"89","author":"D Hall","year":"2016","unstructured":"Hall D, Todorova-Koteva K, Pandya S, Bernard B, Ouyang B, Walsh M, Pounardjian T, Deburghraeve C et al (2016) Neurological and endocrine phenotypes of fragile X carrier women. Clin Genet 89:60\u201367. \n                    https:\/\/doi.org\/10.1111\/cge.12646","journal-title":"Clin Genet"},{"key":"1330_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/clpt.2013.217","volume":"95","author":"R Kaddurah-Daouk","year":"2014","unstructured":"Kaddurah-Daouk R, Weinshilboum RM, Pharmacometabolomics Research N (2014) Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther 95:154\u2013167. \n                    https:\/\/doi.org\/10.1038\/clpt.2013.217","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1330_CR31","doi-asserted-by":"publisher","first-page":"e68283","DOI":"10.1371\/journal.pone.0068283","volume":"8","author":"Hongjie Zhu","year":"2013","unstructured":"Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S, Churchill E, Fiehn O et al (2013) Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder\u2014possible role for methoxyindole pathway. PLoS One 8:\u2013e68283. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0068283","journal-title":"PLoS ONE"},{"key":"1330_CR32","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s13311-017-0555-6","volume":"14","author":"J-Y Wang","year":"2017","unstructured":"Wang J-Y, Trivedi AM, Yang J, Schneider A, Giulivi C, Adams P, Tassone F, Kim K et al (2017) Open label allopregnanolone treatment of men with FXTAS. Neurotherapeutics 14:1073\u20131083. \n                    https:\/\/doi.org\/10.1007\/s13311-017-0555-6","journal-title":"Neurotherapeutics"},{"key":"1330_CR33","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4088\/JCP.13m08546","volume":"75","author":"AL Seritan","year":"2014","unstructured":"Seritan AL, Nguyen DV, Mu Y, Tassone F, Bourgeois JA, Schneider A, Cogswell JB, Cook KR et al (2014) Memantine for fragile X-associated tremor\/ataxia syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 75:264\u2013271. \n                    https:\/\/doi.org\/10.4088\/JCP.13m08546","journal-title":"J Clin Psychiatry"},{"key":"1330_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1373\/clinchem.2009.136101","volume":"56","author":"S Filipovic-Sadic","year":"2010","unstructured":"Filipovic-Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, Hagerman PJ, Stenzel TT et al (2010) A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem 56:399\u2013408. \n                    https:\/\/doi.org\/10.1373\/clinchem.2009.136101","journal-title":"Clin Chem"},{"key":"1330_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fgene.2014.00318","volume":"5","author":"D Pretto","year":"2014","unstructured":"Pretto D, Yrigollen CM, Tang HT, Williamson J, Espinal G, Iwahashi CK, Durbin-Johnson B, Hagerman RJ et al (2014) Clinical and molecular implications of mosaicism in FMR1 full mutations. Front Genet 5:318. \n                    https:\/\/doi.org\/10.3389\/fgene.2014.00318","journal-title":"Front Genet"},{"key":"1330_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/molmed.2016.00122","volume":"22","author":"G Song","year":"2016","unstructured":"Song G, Napoli E, Wong S, Hagerman R, Liu S, Tassone F, Giulivi C (2016) Altered redox mitochondrial biology in the neurodegenerative disorder fragile X-tremor\/ataxia syndrome: use of antioxidants in precision medicine. Mol Med 22:1. \n                    https:\/\/doi.org\/10.2119\/molmed.2016.00122","journal-title":"Mol Med"},{"key":"1330_CR37","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1001\/jama.2010.1706","volume":"304","author":"C Giulivi","year":"2010","unstructured":"Giulivi C, Zhang YF, Omanska-Klusek A, Ross-Inta C, Wong S, Hertz-Picciotto I, Tassone F, Pessah IN (2010) Mitochondrial dysfunction in autism. Jama 304:2389\u20132396. \n                    https:\/\/doi.org\/10.1001\/jama.2010.1706","journal-title":"Jama"},{"key":"1330_CR38","doi-asserted-by":"publisher","first-page":"W251","DOI":"10.1093\/nar\/gkv380","volume":"43","author":"J Xia","year":"2015","unstructured":"Xia J, Sinelnikov IV, Han B, Wishart DS (2015) MetaboAnalyst 3.0\u2014making metabolomics more meaningful. Nucleic Acids Res 43:W251\u2013W257. \n                    https:\/\/doi.org\/10.1093\/nar\/gkv380","journal-title":"Nucleic Acids Res"},{"key":"1330_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00787-010-0087-7","volume":"19","author":"M Szumilas","year":"2010","unstructured":"Szumilas M (2010) Explaining odds ratios. J Can Acad Child Adolesc Psychiatry 19:227\u2013229","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"1330_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1055\/s-2007-973527","volume":"29","author":"KM Gibson","year":"1998","unstructured":"Gibson KM, Hoffmann GF, Hodson AK, Bottiglieri T, Jakobs C (1998) 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics 29:14\u201322. \n                    https:\/\/doi.org\/10.1055\/s-2007-973527","journal-title":"Neuropediatrics"},{"key":"1330_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/bms.1200190207","volume":"19","author":"KM Gibson","year":"1990","unstructured":"Gibson KM, Aramaki S, Sweetman L, Nyhan WL, DeVivo DC, Hodson AK, Jakobs C (1990) Stable isotope dilution analysis of 4-hydroxybutyric acid: an accurate method for quantification in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria. Biomed Environ Mass Spectrom 19:89\u201393. \n                    https:\/\/doi.org\/10.1002\/bms.1200190207","journal-title":"Biomed Environ Mass Spectrom"},{"key":"1330_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF01799979","volume":"10","author":"GK Brown","year":"1987","unstructured":"Brown GK, Cromby CH, Manning NJ, Pollitt RJ (1987) Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: evidence of alpha-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial beta-oxidation. J Inherit Metab Dis 10:367\u2013375. \n                    https:\/\/doi.org\/10.1007\/BF01799979","journal-title":"J Inherit Metab Dis"},{"key":"1330_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0165-6147(99)01341-3","volume":"20","author":"R Bernasconi","year":"1999","unstructured":"Bernasconi R, Mathivet P, Bischoff S, Marescaux C (1999) Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential? Trends Pharmacol Sci 20:135\u2013141","journal-title":"Trends Pharmacol Sci"},{"key":"1330_CR44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0741-8329(99)00092-0","volume":"20","author":"M Maitre","year":"2000","unstructured":"Maitre M, Andriamampandry C, Kemmel V, Schmidt C, Hode Y, Hechler V, Gobaille S (2000) Gamma-hydroxybutyric acid as a signaling molecule in brain. Alcohol 20:277\u2013283","journal-title":"Alcohol"},{"key":"1330_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0387-3","volume":"17","author":"N Karu","year":"2016","unstructured":"Karu N, McKercher C, Nichols DS, Davies N, Shellie RA, Hilder EF, Jose MD (2016) Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study. BMC Nephrol 17:171. \n                    https:\/\/doi.org\/10.1186\/s12882-016-0387-3","journal-title":"BMC Nephrol"},{"key":"1330_CR46","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.2174\/1381612821666150605112105","volume":"21","author":"NM de Bruin","year":"2015","unstructured":"de Bruin NM, Kruse CG (2015) 5-HT6 receptor antagonists: potential efficacy for the treatment of cognitive impairment in schizophrenia. Curr Pharm Des 21:3739\u20133759","journal-title":"Curr Pharm Des"},{"key":"1330_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neubiorev.2015.08.007","volume":"57","author":"CR Kasten","year":"2015","unstructured":"Kasten CR, Boehm SL 2nd (2015) Identifying the role of pre-and postsynaptic GABA(B) receptors in behavior. Neurosci Biobehav Rev 57:70\u201387. \n                    https:\/\/doi.org\/10.1016\/j.neubiorev.2015.08.007","journal-title":"Neurosci Biobehav Rev"},{"key":"1330_CR48","doi-asserted-by":"publisher","first-page":"e10883","DOI":"10.1371\/journal.pone.0010883","volume":"5","author":"WE Gall","year":"2010","unstructured":"Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, Ryals JA, Milburn MV et al (2010) Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 5:e10883. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0010883","journal-title":"PLoS One"},{"key":"1330_CR49","first-page":"205","volume":"13","author":"RS Lord","year":"2008","unstructured":"Lord RS, Bralley JA (2008) Clinical applications of urinary organic acids. Part I: detoxification markers. Altern Med Rev 13:205\u2013215","journal-title":"Altern Med Rev"},{"key":"1330_CR50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.biopsych.2010.12.006","volume":"70","author":"L Capuron","year":"2011","unstructured":"Capuron L, Schroecksnadel S, Feart C, Aubert A, Higueret D, Barberger-Gateau P, Laye S, Fuchs D (2011) Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 70:175\u2013182. \n                    https:\/\/doi.org\/10.1016\/j.biopsych.2010.12.006","journal-title":"Biol Psychiatry"},{"key":"1330_CR51","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.psyneuen.2010.09.012","volume":"36","author":"R Dantzer","year":"2011","unstructured":"Dantzer R, O'Connor JC, Lawson MA, Kelley KW (2011) Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36:426\u2013436. \n                    https:\/\/doi.org\/10.1016\/j.psyneuen.2010.09.012","journal-title":"Psychoneuroendocrinology"},{"key":"1330_CR52","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12311-016-0779-8","volume":"15","author":"E Napoli","year":"2016","unstructured":"Napoli E, Song G, Wong S, Hagerman R, Giulivi C (2016) Altered bioenergetics in primary dermal fibroblasts from adult carriers of the FMR1 premutation before the onset of the neurodegenerative disease fragile X-associated tremor\/ataxia syndrome. Cerebellum 15:552\u2013564. \n                    https:\/\/doi.org\/10.1007\/s12311-016-0779-8","journal-title":"Cerebellum"},{"key":"1330_CR53","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.pnpbp.2013.08.008","volume":"48","author":"AM Myint","year":"2014","unstructured":"Myint AM, Kim YK (2014) Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog Neuro-Psychopharmacol Biol Psychiatry 48:304\u2013313. \n                    https:\/\/doi.org\/10.1016\/j.pnpbp.2013.08.008","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1330_CR54","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/0304-4165(79)90015-1","volume":"587","author":"MD Armstrong","year":"1979","unstructured":"Armstrong MD (1979) N-delta-acetylornithine and S-methylcysteine in blood plasma. Biochim Biophys Acta 587:638\u2013642","journal-title":"Biochim Biophys Acta"},{"key":"1330_CR55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11481-015-9605-1","volume":"10","author":"JL McClay","year":"2015","unstructured":"McClay JL, Vunck SA, Batman AM, Crowley JJ, Vann RE, Beardsley PM, van den Oord EJ (2015) Neurochemical metabolomics reveals disruption to sphingolipid metabolism following chronic haloperidol administration. J NeuroImmune Pharmacol 10:425\u2013434. \n                    https:\/\/doi.org\/10.1007\/s11481-015-9605-1","journal-title":"J NeuroImmune Pharmacol"},{"key":"1330_CR56","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3","journal-title":"Lancet"},{"key":"1330_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1017\/S003329170003960X","volume":"10","author":"CD Marsden","year":"1980","unstructured":"Marsden CD, Jenner P (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10:55\u201372","journal-title":"Psychol Med"},{"key":"1330_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/mp.2011.131","volume":"18","author":"J Yang","year":"2013","unstructured":"Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X et al (2013) Potential metabolite markers of schizophrenia. Mol Psychiatry 18:67\u201378. \n                    https:\/\/doi.org\/10.1038\/mp.2011.131","journal-title":"Mol Psychiatry"},{"key":"1330_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/molmed.2016.00122","volume":"22","author":"G Song","year":"2016","unstructured":"Song G, Napoli E, Wong S, Hagerman R, Liu S, Tassone F, Giulivi C (2016) Altered redox mitochondrial biology in the neurodegenerative disorder fragile X-tremor\/ataxia syndrome: use of antioxidants in precision medicine. Mol Med 22:1. \n                    https:\/\/doi.org\/10.2119\/molmed.2016.00122","journal-title":"Mol Med"},{"key":"1330_CR60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrneurol.2016.147","volume":"12","author":"RD Brinton","year":"2016","unstructured":"Brinton RD (2016) Neuroendocrinology: oestrogen therapy affects brain structure but not function. Nat Rev Neurol 12:561\u2013562. \n                    https:\/\/doi.org\/10.1038\/nrneurol.2016.147","journal-title":"Nat Rev Neurol"},{"key":"1330_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1517\/14728222.5.2.219","volume":"5","author":"SR Kleppner","year":"2001","unstructured":"Kleppner SR, Tobin AJ (2001) GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. Expert Opin Ther Targets 5:219\u2013239. \n                    https:\/\/doi.org\/10.1517\/14728222.5.2.219","journal-title":"Expert Opin Ther Targets"},{"key":"1330_CR62","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ajmg.b.31046","volume":"153B","author":"PE Adams","year":"2010","unstructured":"Adams PE, Adams JS, Nguyen DV, Hessl D, Brunberg JA, Tassone F, Zhang W, Koldewyn K et al (2010) Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet 153B:775\u2013785. \n                    https:\/\/doi.org\/10.1002\/ajmg.b.31046","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1330_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.brainres.2014.01.024","volume":"1552","author":"JM Kim","year":"2014","unstructured":"Kim JM, Kim DH, Lee Y, Park SJ, Ryu JH (2014) Distinct roles of the hippocampus and perirhinal cortex in GABAA receptor blockade-induced enhancement of object recognition memory. Brain Res 1552:17\u201325. \n                    https:\/\/doi.org\/10.1016\/j.brainres.2014.01.024","journal-title":"Brain Res"},{"key":"1330_CR64","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1601-183X.2010.00575.x","volume":"9","author":"L Prut","year":"2010","unstructured":"Prut L, Prenosil G, Willadt S, Vogt K, Fritschy JM, Crestani F (2010) A reduction in hippocampal GABAA receptor alpha5 subunits disrupts the memory for location of objects in mice. Genes Brain Behav 9:478\u2013488. \n                    https:\/\/doi.org\/10.1111\/j.1601-183X.2010.00575.x","journal-title":"Genes Brain Behav"},{"key":"1330_CR65","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00213-003-1673-x","volume":"174","author":"DA Lewis","year":"2004","unstructured":"Lewis DA, Volk DW, Hashimoto T (2004) Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology 174:143\u2013150. \n                    https:\/\/doi.org\/10.1007\/s00213-003-1673-x","journal-title":"Psychopharmacology"},{"key":"1330_CR66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1212\/WNL.0b013e31825dcf71","volume":"79","author":"J Reis","year":"2012","unstructured":"Reis J, Cohen LG, Pearl PL, Fritsch B, Jung NH, Dustin I, Theodore WH (2012) GABAB-ergic motor cortex dysfunction in SSADH deficiency. Neurology 79:47\u201354. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e31825dcf71","journal-title":"Neurology"},{"key":"1330_CR67","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/ejhg.2009.51","volume":"17","author":"L Rodriguez-Revenga","year":"2009","unstructured":"Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, Xuncla M, Badenas C, Kulisevsky J, Gomez B, Mila M (2009) Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet 17:1359\u20131362. \n                    https:\/\/doi.org\/10.1038\/ejhg.2009.51","journal-title":"Eur J Hum Genet"},{"key":"1330_CR68","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.pnpbp.2007.09.017","volume":"32","author":"M Bishnoi","year":"2008","unstructured":"Bishnoi M, Chopra K, Kulkarni SK (2008) Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. Prog Neuro-Psychopharmacol Biol Psychiatry 32:451\u2013461. \n                    https:\/\/doi.org\/10.1016\/j.pnpbp.2007.09.017","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1330_CR69","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1358\/mf.2008.30.9.1186076","volume":"30","author":"A Singh","year":"2008","unstructured":"Singh A, Kumar A (2008) Possible GABAergic modulation in the protective effect of allopregnanolone on sleep deprivation-induced anxiety-like behavior and oxidative damage in mice. Methods Find Exp Clin Pharmacol 30:681\u2013689. \n                    https:\/\/doi.org\/10.1358\/mf.2008.30.9.1186076","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"1330_CR70","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/prot.24937","volume":"83","author":"G Tamazian","year":"2015","unstructured":"Tamazian G, Ho Chang J, Knyazev S, Stepanov E, Kim KJ, Porozov Y (2015) Modeling conformational redox-switch modulation of human succinic semialdehyde dehydrogenase. Proteins 83:2217\u20132229. \n                    https:\/\/doi.org\/10.1002\/prot.24937","journal-title":"Proteins"},{"key":"1330_CR71","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1046\/j.1471-4159.2003.01839.x","volume":"86","author":"TC Murphy","year":"2003","unstructured":"Murphy TC, Amarnath V, Gibson KM, Picklo MJ Sr (2003) Oxidation of 4-hydroxy-2-nonenal by succinic semialdehyde dehydrogenase (ALDH5A). J Neurochem 86:298\u2013305","journal-title":"J Neurochem"},{"key":"1330_CR72","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1006\/taap.2002.9506","volume":"184","author":"MJ Picklo","year":"2002","unstructured":"Picklo MJ, Montine TJ, Amarnath V, Neely MD (2002) Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 184:187\u2013197","journal-title":"Toxicol Appl Pharmacol"},{"key":"1330_CR73","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/hmg\/ddr211","volume":"20","author":"E Napoli","year":"2011","unstructured":"Napoli E, Ross-Inta C, Wong S, Omanska-Klusek A, Barrow C, Iwahashi C, Garcia-Arocena D, Sakaguchi D et al (2011) Altered zinc transport disrupts mitochondrial protein processing\/import in fragile X-associated tremor\/ataxia syndrome. Hum Mol Genet 20:3079\u20133092. \n                    https:\/\/doi.org\/10.1093\/hmg\/ddr211","journal-title":"Hum Mol Genet"},{"key":"1330_CR74","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ymgme.2017.04.005","volume":"121","author":"AD Kennedy","year":"2017","unstructured":"Kennedy AD, Pappan KL, Donti TR, Evans AM, Wulff JE, Miller LAD, Reid Sutton V, Sun Q et al (2017) Elucidation of the complex metabolic profile of cerebrospinal fluid using an untargeted biochemical profiling assay. Mol Genet Metab 121:83\u201390. \n                    https:\/\/doi.org\/10.1016\/j.ymgme.2017.04.005","journal-title":"Mol Genet Metab"},{"key":"1330_CR75","doi-asserted-by":"publisher","first-page":"e63644","DOI":"10.1371\/journal.pone.0063644","volume":"8","author":"E Trushina","year":"2013","unstructured":"Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC (2013) Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One 8:e63644. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0063644","journal-title":"PLoS One"},{"key":"1330_CR76","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1586\/14789450.4.4.435","volume":"4","author":"JL Griffin","year":"2007","unstructured":"Griffin JL, Salek RM (2007) Metabolomic applications to neuroscience: more challenges than chances? Expert Rev Proteomics 4:435\u2013437. \n                    https:\/\/doi.org\/10.1586\/14789450.4.4.435","journal-title":"Expert Rev Proteomics"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-018-1330-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T13:30:04Z","timestamp":1589895004000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-018-1330-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1007\/s12035-018-1330-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"22 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RJH has received funding from Novartis, Roche\/Genentech, Alcobra, and Neuren for treatment trials in fragile X syndrome, autism, and Down syndrome. She has also consulted with Novartis, Fulcrum, Zynerba, and Roche\/Genentech regarding treatment for fragile X syndrome. The other authors have no conflicts of financial interest relevant to this article to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}